Perjeta 420mg Injection

About

Perjeta 420mg Injection, containing pertuzumab, is a monoclonal antibody specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein. It works by binding to subdomain II of the HER2 extracellular domain, which is critical for HER2 dimerization with other HER family receptors (like HER1, HER3, and HER4). By blocking this dimerization, pertuzumab inhibits ligand-initiated intracellular signaling pathways that are involved in cell growth and survival, thereby suppressing tumor proliferation.

Perjeta is indicated for the treatment of HER2-positive breast cancer, typically in combination with trastuzumab and chemotherapy. This dual HER2 blockade strategy provides a more comprehensive and potent anti-tumor effect compared to single-agent HER2 targeting. It is used in both early-stage (neoadjuvant and adjuvant settings) and metastatic HER2-positive breast cancer to improve patient outcomes, including pathological complete response rates and progression-free survival. Cardiac function monitoring is essential during treatment.

Uses

• Neoadjuvant treatment of HER2-positive early breast cancer.
• Adjuvant treatment of HER2-positive early breast cancer.
• Treatment of HER2-positive metastatic breast cancer.
• Used in combination with trastuzumab and chemotherapy.

Directions For Use

Perjeta 420mg Injection is administered intravenously by a healthcare professional. The initial dose is typically higher, followed by maintenance doses every three weeks.

Benefits

• Targets HER2 dimerization for comprehensive blockade.
• Significantly improves outcomes in HER2-positive breast cancer.
• Effective in both early and metastatic disease.
• Used in combination with other HER2-targeted therapies.
• Part of established treatment protocols.
• Helps to prevent disease recurrence and progression.

Side Effects

• Diarrhea
• Nausea
• Alopecia (hair loss)
• Fatigue
• Neutropenia
• Anemia
• Peripheral neuropathy
• Rash
• Musculoskeletal pain
• Cardiomyopathy (heart muscle weakness)
• Infusion-related reactions
• Hypersensitivity reactions

Safety Measures

• Alcohol - No specific contraindication, but alcohol may worsen general side effects like nausea or fatigue. Consult your doctor.
• Pregnancy - Perjeta can cause oligohydramnios and fetal renal impairment. Avoid use during pregnancy. Women of reproductive potential must use effective contraception.
• Breastfeeding - It is unknown if Perjeta is excreted in human milk. Due to potential harm to the infant, breastfeeding is not recommended during treatment and for 7 months after the last dose.
• Liver - No specific dose adjustment is required for hepatic impairment. However, monitor liver function as part of general patient management.
• Kidney - No specific dose adjustment is required for renal impairment. Monitor kidney function as part of general patient management.
• Lung - Monitor for signs of pulmonary toxicity, including dyspnea, cough, and fever. Discontinue if severe pulmonary adverse events occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.